	US 12,029,732 B2
	Treatment of vascular and lymphatic disease
Tamara Terzian, Aurora, CO (US); and Neil Box, Aurora, CO (US)
Assigned to The Regents of the University of Colorado, A Body Corporate, Denver, CO (US)
Appl. No. 17/604,858
Filed by THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, Denver, CO (US)
PCT Filed Apr. 20, 2020, PCT No. PCT/US2020/029015 § 371(c)(1), (2) Date Oct. 19, 2021, PCT Pub. No. WO2020/215091, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/990,932, filed on Mar. 17, 2020.
Claims priority of provisional application 62/836,535, filed on Apr. 19, 2019.
Prior Publication US 2022/0218674 A1, Jul. 14, 2022
Int. Cl. A61K 31/428 (2006.01); A61K 31/429 (2006.01); A61P 7/10 (2006.01)

CPC A61K 31/428 (2013.01) [A61K 31/429 (2013.01); A61P 7/10 (2018.01)]

18 Claims

1. A method of treating a subject at risk for developing a disease or condition associated with lymphatic vasculature, the method comprising:

reducing activity of p53 in a subject at risk for or suffering from a disease or condition associated with lymphatic vasculature.